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Evidence for histidine-rich protein 2 
immune complex formation in symptomatic 
patients in Southern Zambia
Christine F. Markwalter1, Lwiindi Mudenda1,3, Mindy Leelawong1, Danielle W. Kimmel1, Armin Nourani1, 
Saidon Mbambara2, Philip E. Thuma2 and David W. Wright1* 
Abstract 
Background: Rapid diagnostic tests based on histidine-rich protein 2 (HRP2) detection are the primary tools used to 
detect Plasmodium falciparum malaria infections. Recent conflicting reports call into question whether α-HRP2 anti-
bodies are present in human host circulation and if resulting immune complexes could interfere with HRP2 detection 
on malaria RDTs. This study sought to determine the prevalence of immune-complexed HRP2 in a low-transmission 
region of Southern Zambia.
Methods: An ELISA was used to quantify HRP2 in patient sample DBS extracts before and after heat-based immune 
complex dissociation. A pull-down assay reliant on proteins A, G, and L was developed and applied for IgG and 
IgM capture and subsequent immunoprecipitation of any HRP2 present in immune complexed form. A total of 104 
patient samples were evaluated using both methods.
Results: Immune-complexed HRP2 was detectable in 17% (18/104) of all samples evaluated and 70% (16/23) of 
HRP2-positive samples. A majority of the patients with samples containing immune-complexed HRP2 had P. falcipa-
rum infections (11/18) and were also positive for free HRP2 (16/18). For 72% (13/18) of patients with immune-com-
plexed HRP2, less than 10% of the total HRP2 present was in immune-complexed form. For the remaining samples, a 
large proportion (≥ 20%) of total HRP2 was complexed with α-HRP2 antibodies.
Conclusions: Endogenous α-HRP2 antibodies form immune complexes with HRP2 in the symptomatic patient 
population of a low-transmission area in rural Southern Zambia. For the majority of patients, the percentage of HRP2 
in immune complexes is low and does not affect HRP2-based malaria diagnosis. However, for some patients, a sig-
nificant portion of the total HRP2 was in immune-complexed form. Future studies investigating the prevalence and 
proportion of immune-complexed HRP2 in asymptomatic individuals with low HRP2 levels will be required to assess 
whether α-HRP2 antibodies affect HRP2 detection for this portion of the transmission reservoir.
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Background
Antigen-detecting rapid diagnostic tests (RDTs) have 
been workhorses for detection of malaria at the point 
of care, accounting for 63% of diagnostic testing of sus-
pected cases in 2016 [1]. In the same year, the World 
Health Organization estimates that 312 million RDTs 
were delivered globally [1]. These common tests are most 
often formatted as lateral flow assays, which use antibod-
ies to capture and detect malarial parasite proteins.
Approximately 75% of the RDTs delivered in 2016 
detected only Plasmodium falciparum, which is the most 
prevalent species of human malaria and is responsible 
for the majority of severe malaria cases and mortality 
worldwide [1]. Most RDTs specific for this species rely 
on the detection of P. falciparum histidine-rich protein 
2 (HRP2), which was the first antigen targeted in com-
mercial tests [2]. HRP2 is a 30 kDa water-soluble protein 
found in the parasite and host erythrocyte cytoplasm and 
on the surface of infected red blood cells [3]. The precise 
function of HRP2 remains unconfirmed, though the pri-
mary structure of HRP2 is highly unique; histidine com-
prises more than 30% of the primary sequence, which 
consists largely of AHHAHHAAD and AHHAAD repeat 
motifs [4]. A cleavable sequence at the N-terminus is 
responsible for export of HRP2, which diffuses into host 
plasma, allowing for detection in peripheral blood [3, 5]. 
Clinical concentrations of HRP2 can range from 100 fM 
to 100  nM, though expression of HRP2 varies over the 
erythrocytic life cycle of the parasite [6–9]. The unique 
structure of HRP2 makes it an advantageous biomarker 
for malaria detection; multiple epitope copies on a single 
protein result in high-avidity interactions with antibodies 
present in RDTs, leading to effective capture and detec-
tion of HRP2. Thus, it is not surprising that the most sen-
sitive RDTs on the market are based on HRP2 detection, 
though performance varies significantly by manufacturer 
[10].
Despite these advantages, there are several drawbacks 
to using HRP2 as the sole diagnostic marker for P. fal-
ciparum infections. The biomarker has been shown to 
persist in circulation up to 52  days beyond successful 
treatment and parasite clearance [9, 11]. Thus, an HRP2-
based test is unable to distinguish between active and 
recently cleared P. falciparum infections. Additionally, 
HRP2 is not essential to parasite survival, and clinical iso-
lates with pfhrp2 gene deletions have been observed with 
increasing frequency around the world [12–18]. Infec-
tions lacking pfhrp2 will result in false-negative results on 
HRP2-based malaria rapid diagnostics and can threaten 
elimination efforts.
Another potential source of false-negative RDT results 
in P. falciparum-infected individuals could be the pres-
ence of HRP2-specific antibodies (α-HRP2) produced as 
part of the host immune response to malaria infection. 
Although there is significant precedent for endogenous 
antibody interference with immunochromatographic 
detection of other infectious diseases, including HIV 
[19, 20], dengue [21, 22], and tuberculosis [23, 24], only 
a handful of studies have been published on the poten-
tial effects of endogenous α-HRP2 antibodies on bio-
marker detectability [25–28]. In the first of these studies, 
Biswas et al. measured HRP2 and α-HRP2 in the serum 
of patients in India with acute P. falciparum infections 
before treatment and over 28  days after treatment [25]. 
HRP2 decreased gradually over time, with HRP2-spe-
cific IgM following the same pattern. Anti-HRP2 IgG 
titres increased gradually over the 28 days. Importantly, 
3 patients who were RDT-negative and microscopy-pos-
itive upon enrollment had significantly higher α-HRP2 
IgM and IgG titres compared to the 42 RDT-positive 
individuals, indicating that the presence of these circulat-
ing antibodies could interfere with HRP2-specific RDTs 
[25]. More recently, Ho et al. found endogenous α-HRP2 
antibodies were present in the plasma of 25% of sympto-
matic malaria patients from Cambodia, Nigeria, and the 
Philippines and 11% of asymptomatic individuals in the 
Solomon Islands [27]. The group also found that incu-
bating serum from high α-HRP2-titre individuals with 
in  vitro parasite culture resulted in a marked decrease 
in RDT signal for several RDT brands [27]. Both of 
these studies suggest that the humoral immune response 
against HRP2 could decrease the detectability of HRP2, 
resulting in false-negative RDT readings.
In direct contrast to the aforementioned reports, two 
investigations have found an absence of endogenous 
α-HRP2 antibodies in patients from malaria-endemic 
regions. In a study aimed to determine the immunomod-
ulatory properties of the biomarker, Das et al. found that 
PBMCs isolated from P. falciparum-exposed patients in 
India did not produce a detectable HRP2-specific anti-
body response when stimulated with the antigen [26]. 
Most recently, Taylor et  al. evaluated plasma samples 
from Cameroonian individuals living in a region with 
high P. falciparum transmission with the goal of deter-
mining the prevalence, class, subclass, and avidity of cir-
culating α-HRP2 antibodies [28]. Although these patients 
had robust levels of antibodies specific for other P. falci-
parum antigens, including three malaria merozoite sur-
face proteins (MSP1, MSP2, and MSP3), the levels of 
detectable circulating α-HRP2 antibodies were no differ-
ent from those of malaria-naïve control patients from the 
United States.
These discordant results in the literature led to this 
investigation of whether individuals living in a low-trans-
mission region in Southern Zambia produce HRP2-spe-
cific antibodies that could interfere with HRP2 detection. 
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However, unlike the four published studies, all of which 
detected freely available circulating α-HRP2 using a 
direct immunoassay format, this work specifically sought 
to determine whether patient samples contain HRP2 
immune complexes. (Note: in this study, immune com-
plexes refer to antibodies bound to antigen.) To do this, 
magnetic particles were used to isolate IgG and IgM 
(free and complexed) from patient sample dried blood 
spot (DBS) extracts. The captured antibodies were then 
exposed to denaturing immunoprecipitation conditions 
in order to release any complexed HRP2, which was sub-
sequently measured by ELISA. Additionally, free HRP2 
in untreated and heated DBS extracts was measured to 
determine whether signal could be enhanced by dissoci-
ating any immune complexes present.
Methods
Reagents and materials
Human whole blood (CPD) was purchased from Biorec-
lamation IVT (catalog no. HMWBCPD). Recombi-
nant HRP2 protein (rcHRP2) was generously provided 
by PATH (Seattle, WA). Plasmodium falciparum D6 
strain was cultured in-house.  Dynabeads® Protein A, 
 Dynabeads® Protein G, and Pierce Protein L Magnetic 
Particles were purchased from Fisher Scientific (10-002-
D, 10-004-D, PI88850). Anti-HRP2 antibodies were pur-
chased from Abcam (ab9203, ab9206, ab30384). TMB 
One was purchased from Promega (G7431). 903 Protein 
Saver Cards were purchased from GE Healthcare Life 
Sciences (10534612). A Fisher Scientific Analog Vortex 
Mixer (02-215-365) was used for all vortexed incuba-
tions. A VWR Digital Dry Heatblock (12621-086) with an 
external thermocouple (11301-112) was used for sample 
heating. Absorbance was measured on a Biotek Synergy 
H4 microplate reader (Vanderbilt University) or Biotek 
ELx808 microplate reader (Macha Research Trust). All 
other reagents and materials were purchased from either 
Fisher Scientific or Sigma Aldrich.
HRP2 enzyme‑linked immunosorbent assay (ELISA)
A previously reported HRP2 ELISA protocol was 
employed [9, 29]. Briefly, 100 µl of 1 µg/ml α-HRP2 IgM 
(ab9206, clone PTL3) was added to the wells of an Immu-
lon 2HB 96-well plate for 1  h. After 3 washes with 1× 
phosphate buffered saline with 0.1% Tween-20 (PBST), 
the plate was blocked with 300  µl of 5% BSA in PBST 
for 2  h. Standards and samples (100  µl) in ELISA sam-
ple buffer (PBST with 0.1% BSA) were then added to the 
plate for 2  h. Next, 100  µl of 0.5  µg/ml α-HRP2 conju-
gated to horseradish peroxidase (HRPx) (ab30384, clone 
MPFG55P) in PBST with 0.5% BSA was added for 1  h 
while protected from light. Signal was generated using 
TMB One solution, and the reaction was stopped with 
2  M  H2SO4 after 10  min. Absorbance was measured at 
450 nm. For all ELISAs performed in this study, the aver-
age LOD was 0.012 ± 0.004  pM rcHRP2. The average 
intra-assay variability was 3.4% and the inter-assay vari-
ability was 22%.
Dried blood spot (DBS) preparation and extraction
To prepare control mock DBS patient samples, in-house 
P. falciparum D6 culture (stock: 43,600  parasites/µl) 
and a high affinity α-HRP2 mouse monoclonal antibody 
(ab9203, clone C1–13) were spiked into whole blood to 
desired concentrations and spotted (10  µl) onto Protein 
Saver 903 cards. The DBS were air-dried for a minimum 
of 4  h and a maximum of overnight. A modified office 
hole-punch (Office  Depot® #825232 with punch tray 
removed) was used to remove DBS from the cards. Five 
punches of clean DBS cards were performed between 
each sample punch to minimize cross-contamination. 
Each DBS was placed in a 2-ml microcentrifuge tube, and 
300 µl of PBST was added to each tube. The tubes were 
placed on a vortexer at maximum speed (3200 rpm) for 
10 min and then a mini-centrifuge for 1 min to remove 
bubbles. The supernatant was removed and reserved for 
analysis. For each sample, half of the DBS extract super-
natant was added to a separate 2-ml microcentrifuge 
tube and placed on an 80 °C heat block for 10 min. These 
heated samples were then allowed to cool to room tem-
perature before ELISA analysis.
DBS ELISA
ELISA plates were prepared as described above. Heated 
and untreated DBS extracts were diluted tenfold in 
ELISA sample buffer (PBST with 0.1% BSA), and 100 µl 
of each diluted sample was placed on the plate in dupli-
cate. Each plate also contained an rcHRP2 standard curve 
(0–10  pM) in sample buffer. Incubation times, washes, 
and addition of detection antibody, HRPx substrate, and 
quenching solution were identical to the HRP2 ELISA 
protocol above. Signal was measured at 450 nm.
HRP2 immune complex pull‑down assay
In order to determine the amount of HRP2 complexed 
with antibodies in each sample, 10  µl of untreated DBS 
extract was added to 40  µl of PBST in a 1.5-ml micro-
centrifuge tube. Next, 30  µl of a 1:1:1 mixture (10  mg/
ml) of  Dynabeads® Protein G,  Dynabeads® Protein A, 
and Pierce™ Protein L magnetic beads was added to the 
diluted DBS extract, and samples were incubated on a 
vortexer (3200  rpm) for 10  min. Using a magnetic tube 
holder (Invitrogen MagnaRack CS15000), the superna-
tant was removed. Next, the magnetic beads were washed 
by vortexing with 50 µl of PBST, and the wash superna-
tant was removed using the magnetic tube holder. To 
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elute any HRP2 complexed to antibodies captured by the 
beads, a classic denaturing immunoprecipitation proto-
col was followed: 40 µl of 0.5 M glycine buffer (pH 3) was 
added to the beads, which were vortexed and then placed 
on an 80  °C heat block for 10  min. Using the magnetic 
rack, the supernatant was removed from the beads and 
placed in a 1.5-ml microcentrifuge tube before the addi-
tion of 15 µl 1 M TRIS pH 8. After neutralization, 50 µl of 
ELISA sample buffer was added to each tube. This pro-
cess was performed in duplicate for each sample. Thus 
two 100-µl neutralized and diluted samples were placed 
on an ELISA plate to measure HRP2 concentrations for 
each DBS sample. ELISAs were carried out as described 
above.
Study setting, patient recruitment, and ethics
Clinical DBS samples were collected in the catchment 
area of Macha Mission Hospital in Choma District, 
Southern Province, Zambia, a rural 1200 km2 area where 
roughly 30,000 individuals live [30]. In this region, there 
is a single rainy season from November through April 
in which malaria transmission peaks, though the preva-
lence of malaria has declined steadily over the last decade 
to less than 1% [31, 32]. Patients were enrolled into the 
present study from both passive and reactive surveillance 
settings. For the former, patients presenting to Macha 
Mission Hospital with fever (> 37.5  °C) were prescribed 
a malaria RDT (SD Bioline Pf ) according to Hospital pro-
tocol. After provision of written informed consent and 
completion of a questionnaire, capillary whole blood was 
collected by finger prick once the prescribed RDT was 
performed. In the case of minors under 18 years of age, 
consent and survey responses were requested from a par-
ent or guardian. As fever was a requirement for recruit-
ment in the clinic, all patients providing samples in this 
setting were classified as symptomatic. 49 patients were 
enrolled in the Hospital setting in March and April 2017. 
In addition to the clinic setting, patients already enrolled 
in Step D of the reactive screen-and-treat efforts imple-
mented in this area of Southern Province, Zambia were 
recruited for this study [33]. These patients were either 
known index malaria cases, living in the same household 
as an index case, or living in a household located within 
140 m of an index case. Patients were recruited for this 
study only if they or a parent/guardian provided writ-
ten informed consent. Finger prick capillary blood was 
collected after the prescribed RDT (SD Bioline Pf ) for 
Step D surveillance was performed. In this reactive sur-
veillance setting, 55 patients were enrolled in March–
April 2017. A total of 104 samples were analysed in this 
study. This study and sample collection were performed 
under IRB approval (MRT IRB # E.2014.01.v4.0) and 
after approval for the study was granted by the Zambian 
National Health Research Authority (MH/101/23/10/1).
Patient sample DBS preparation and storage
Finger-prick whole blood samples were collected in 
300  µl SAFE-T-FILL Capillary Blood Collection Tubes 
containing sodium citrate (Ram Scientific). Whole blood 
samples (5  µl) were run on Paracheck Pf RDTs, which 
were measured using an ESEQuant Lateral Flow Reader 
(Qiagen) with a cut-off of 30 mV. Next, 10 µl spots were 
placed on Protein Saver 903 cards and allowed to dry 
at room temperature overnight. Samples were either 
punched and analysed the next morning or placed in 
a zip-lock bag with desiccant and stored at − 80  °C. All 
samples were analysed in April and May 2017.
DNA extraction and PCR amplification
DNA was extracted from the dried blood spots using 
the Chelex method as previously described [34], with 
minor modifications. The spots were punched out with a 
6.35 mm hole punch directly into 1 ml of a 0.1% saponin 
solution and incubated at room temperature for 10 min. 
After discarding the supernatant, PBS was used to rinse 
the spot, and 150 µl of 2% Chelex-100 and 50 µl of water 
were added. Samples were incubated at 100 °C for 8 min. 
The tubes were centrifuged, and the supernatant was col-
lected. Samples were stored at − 20 °C. Real-time PCR to 
detect the P. falciparum 18S gene was performed with the 
previously described Fal-F [35] and Plasmo2-R primers 
and the Falc 6-carboxyfluorescein (FAM)-labelled probe 
[36]. The primers were used at a concentration of 200 nM 
each and the probe at 50 nM in QuantiFast Probe PCR 
Master Mix (Qiagen). Samples and controls were run 
in triplicate. A standard curve was included with each 
96-well plate. Reactions were amplified and analysed with 
the Roche Lightcycler 480 II using the following cycling 
conditions: initial denaturation at 95 °C for 5 min and 45 
cycles of 95 °C for 10 s and 60 °C for 30 s.
Determination of free and immune‑complexed HRP2 
in patient samples
Two DBS per patient sample were extracted. Half of the 
DBS supernatant was reserved (“untreated”), and the 
remainder was heated on an 80 °C heat block for 10 min. 
20  µl of untreated DBS extract was used to determine 
the amount of HRP2 complexed with antibodies using 
the protein A/G/L extraction protocol described above 
in duplicate. Additionally, the untreated and heated DBS 
extracts were diluted tenfold in ELISA sample buffer, 
and a DBS ELISA was performed in duplicate as detailed 
above. Samples for which signal did not fall in the lin-
ear range were re-run at the appropriate dilutions. Note 
that in this manuscript, “free” HRP2 refers to HRP2 not 
Page 5 of 11Markwalter et al. Malar J  (2018) 17:256 
bound in immune complexes regardless of whether it 
was solubilized in the plasma or originated from within 
infected erythrocytes.
Data analysis
HRP2 concentrations were interpolated from rcHRP2 
standard curves run on each plate. Limits of detection 
were calculated as the concentration at which the absorb-
ance was equal to sblank + 3SDblank. Intra- and inter-assay 
variability (%CV) were determined as the average rela-
tive standard deviation of duplicate measurements on 
a single plate and the average relative standard devia-
tions of all measurements at each concentration on the 
standard curve across all assays performed over the 
duration of the study, respectively. All error bars repre-
sent the standard error of measurement. Where appli-
cable, Spearman correlation coefficients were calculated 
when the data were found to not be normally distributed 
according to the D’Agostino and Pearson normality test. 
A paired t test was used to determine whether the meas-
urable [HRP2] was significantly different in untreated 
and heated samples (α = 0.05). An individual sample was 
defined as “enhanced” if the concentration of HRP2 in the 
heated sample was significantly greater than that in the 
untreated sample (one-sided t-test, α = 0.05). A sample 
was determined to contain HRP2 complexed to IgG or 
IgM if the concentration measured in the protein A/G/L 
extraction protocol was significantly different from the 
limit of detection of the HRP2 ELISA (Student’s t-test, 
α = 0.05).
Results
Dissociation of pre‑formed HRP2 immune complexes
A series of laboratory controls were performed before 
analysis of patient samples. First, rcHRP2 was incu-
bated with varying equivalents of a mouse monoclonal 
antibody (clone C1–13), which was previously shown 
to have excellent affinity for rcHRP2 [37]. A portion of 
these HRP2-antibody mixtures was then heated to 80 °C 
for 20  min, and the detectable HRP2 concentrations in 
both untreated and heated samples were measured by 
ELISA. The C1–13 clone was not employed in the ELISA 
protocol. As shown in Fig.  1, α-HRP2 antibodies inter-
fere with ELISA detection of HRP2 by forming immune 
complexes. Heating samples at 80  °C dissociates these 
complexes and completely restores ELISA signal, regard-
less of α-HRP2 excess. This dissociation was found to be 
irreversible. Fully restored HRP2 ELISA signal was main-
tained even after allowing dissociated samples to cool 
for several hours. This is consistent with the literature; 
Leow et  al. reported the melting temperature of C1–13 
as 72 °C, and the rapid rate of heating in this experiment 
(i.e. placing samples directly on an 80 °C heat block) likely 
resulted in irreversible precipitation of the denatured IgG 
[38, 39]. Additional optimization found that 5 min heat-
ing time was sufficient to fully dissociate complexes, so 
a final heating time of 10  min was chosen for further 
experiments.
Optimization of HRP2 immune complex pull‑down assay
A pull-down assay was developed to determine the quan-
tity of HRP2 complexed with antibodies in a given sam-
ple. Magnetic particles functionalized with Proteins A, 
G, and L were incubated with diluted DBS extracts in 
order to capture all IgG and IgM from a sample. These 
beads were washed with buffer before they were sub-
jected to denaturing immunoprecipitation conditions 
that released any complexed HRP2. The supernatant was 
removed and neutralized, and HRP2 was quantified by 
ELISA. To optimize this process, rcHRP2 (500 pM) and 
20 equivalents of C1–13 (10 nM) were spiked into whole 
blood, incubated for 10  min to allow immune complex 
formation, and spotted onto DBS cards. It was found 
that DBS extracts required a minimum fivefold dilution 
in order to maximize HRP2 capture, and multiple bead 
mixing techniques (vortexer, orbital microplate shaker, 
and rotisserie) were found to perform similarly to one 
another (Additional file  1: Fig. S1). The final optimized 
system successfully captured 90% of HRP2 in the sample, 
and the immunoprecipitation protocol released 70% of 
the captured biomarker. Thus, the pull-down assay suc-
cessfully detected approximately 60% of HRP2 when all 
antigen was bound in immune complexes (Fig. 2).
Evaluation of immune complex dissociation and pull‑down 
assay in mock patient samples
In order to evaluate the optimized immune complex 
dissociation and pull-down protocols, a panel of mock 
patient samples was prepared by spiking in-house D6 P. 


















Fig. 1 Increasing equivalents of α-HRP2 antibodies reduced free 
HRP2 detectable by ELISA by forming immune complexes. Heating 
samples at 80 °C for 20 min dissociated these complexes, completely 
restoring ELISA signal, regardless of α-HRP2 excess
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falciparum culture and C1–13 antibodies into human 
whole blood. The panel of mock samples was designed to 
test the limits of the optimized systems and included the 
following whole blood controls: (1) no parasites and no 
C1–13, (2) no parasites with C1–13 (50  nM) (3) varied 
parasite concentration (up to 6400  parasites/µl) and no 
C1–13, (4) constant parasite concentration (2000  para-
sites/µl) with varied C1–13 (up to 100 nM), and (5) var-
ied parasite concentration with constant C1–13 (50 nM). 
These DBS samples were analysed according to the opti-
mized dissociation and pull-down protocols.
As shown in Fig. 3a, in the absence of C1–13, no HRP2 
was detected in the immune complex pull-down assay, 
even at high parasite densities. Importantly, this demon-
strated that only HRP2 complexed to α-HRP2 antibod-
ies, and not free HRP2, is pulled down in the bead-based 
assay, regardless of the magnitude of HRP2 concen-
tration present. The data in Fig.  3a also demonstrated 
that no signal is lost when samples containing only free 
HRP2 are subjected to heating. Additionally, the immune 
complex pull-down assay worked well over a broad range 
of α-HRP2 C1–13 concentrations, and dissociating com-
plexed samples by heating completely restored positive 
signal (Fig.  3b). The pull-down assay also demonstrated 
the expected 60% HRP2 recovery over a broad range of 
parasite concentrations in the presence of excess C1–13 
(Fig.  3c). Taken together, these data show that the opti-
mized protocols behaved as expected for all controls in 
samples that closely mimicked patient dried blood spot 
samples.
Free HRP2 levels in untreated and heated patient DBS 
extracts
A total of 104 patient samples were analysed in this 
study. P. falciparum infection status was determined 
by PCR, and HRP2 was measured by ELISA. As shown 
in Table  1, 81 (78%) recruited patients had no P. fal-
ciparum infection and no detectable free HRP2. The 
remaining 23 samples (22%) were HRP2-positive, 13 of 
which were parasitaemic according to PCR. All individ-
uals with P. falciparum infections had detectable HRP2 
levels. Overall, a positive association between para-
sitaemia and detectable free HRP2 was found (Spear-
man coefficient: 0.7623, P < 0.0001) (Fig. 4). The results 
of heating DBS extracts are shown in Fig.  5a. Heating 











Fig. 2 Using the optimized conditions for the immune complex 
pull-down assay, 90% of complexed HRP2 was captured and 70% of 
the captured biomarker was eluted, resulting in an overall recovery of 
about 60%. Note that these results originated from samples in which 
all detectable HRP2 was initially complexed to C1–13


















Constant 2000 parasites/ l











































Fig. 3 Evaluation of optimized immune complex dissociation protocol and pull-down assay in mock patient samples. a In the absence of α-HRP2 
antibodies, no HRP2 was detectable in the immune complex pull-down assay. Additionally, heating free HRP2 did not diminish ELISA signal. b 
Increasing equivalents of α-HRP2 C1–13 decreased ELISA signal, but heating fully restored that signal. c Immune complex pull-down recovered 60% 
of complexed HRP2 over a wide range of parasite concentrations
Table 1 Patient samples stratified by  collection strategy, 
Pf PCR results, and detectable free HRP2







− − 35 46 81
− + 3 7 10
+ + 11 2 13
Total 49 55 104
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DBS extracts did not result in an overall higher con-
centration of detectable HRP2 compared to untreated 
samples (paired t-test, P = 0.1898). On an individual 
level, a significant increase in detectable HRP2 was 
observed in 6 patient samples (P < 0.05). All patients for 
which HRP2 detectability in DBS extracts was signifi-
cantly enhanced by heating were parasitaemic, and the 
initial free [HRP2] in the corresponding DBS extracts 
was greater than 600 pM. Among these 6 samples, the 
average signal enhancement factor was found to be 
1.3 ± 0.2. In other words, in these 6 samples, 30% more 
HRP2 was detectable in the heated samples compared 
to the untreated samples.  
HRP2 present in immune complexes in patient DBS 
extracts
Immune-complexed HRP2 was detected in the DBS 
extracts of 18 patient samples, which represents 17% 
(18/104) of all samples evaluated and 70% (16/23) of 
samples with detectable free HRP2. As shown in Table 2, 
2/18 of the samples containing immune-complexed 
HRP2 were PCR-negative and did not have detectable 
free HRP2 (i.e. all HRP2 was in complexed form); 5/18 
samples with immune complexes were PCR-negative and 
had detectable free HRP2 (likely recently resolved infec-
tions); and 11/18 were PCR-positive and had detectable 
free HRP2. Only 6/18 of the samples found to contain 
immune-complexed HRP2 were collected in the reac-
tive case detection setting. The median percent of total 
HRP2 present in immune complexes was 2.7% (range 
0.17–100%). As visualized in Fig.  6, the percent of total 
HRP2 present in immune complexes was less than 10% 
for most patient samples containing HRP2 immune com-
plexes. However, for 5 patient samples, 20% or more of 
total HRP2 was present in immune-complexed form. 
Immune-complexed HRP2 was not found in 7/23 
samples with detectable HRP2 in untreated DBS 
extracts. The average free [HRP2] in this group was 
not significantly different from samples in which com-
plexed HRP2 was detected (P = 0.4311). Additionally, 
there was no significant difference in parasite densi-
ties (determined by PCR) between the two groups 
(P = 0.3072), though most samples without detectable 
immune-complexed HRP2 were from patients who did 


















Fig. 4 Relationship between free [HRP2] and parasitaemia at 
the time of sample collection. A significant positive association 







































Fig. 5 Dissociation and pull-down of HRP2 immune complexes in patient samples from rural Southern Zambia. a Heat dissociation of HRP2 
immune complexes did not result in a statistically significant overall enhancement effect. Grey color indicates samples in which immune 
complexed HRP2 was detected using the pull-down assay. b Relationship between the % of HRP2 in complexed form and the total HRP2 in patient 
DBS samples
Table 2 Patient samples stratified by presence of immune 
complexed HRP2, Pf PCR results, and detectable free HRP2







− − 2 79 81
− + 5 5 10
+ + 11 2 13
Total 18 86 104
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not have detectable parasitaemia at the time of sam-
ple collection. In the context of the heat dissociation 
results, free HRP2 signal was significantly enhanced 
after heating for only 5 (28%) of the samples with 
detectable immune-complexed HRP2. This discrep-
ancy could arise from the fact that, for many samples 
with immune-complexed HRP2, the percent of total 
[HRP2] in complexed form was so low that differences 
in [HRP2] after dissociation could not be distinguished 
by duplicate ELISA measurements.
HRP2 detectability by RDT
The RDT results (Paracheck Pf ) for each patient are 
shown in Additional file  1: Table  S1. The overall sen-
sitivity and specificity of the Paracheck Pf RDTs were 
found to be 78% and 90%, respectively, with the ELISA 
results for free HRP2 treated as the gold standard. 
For the group of 18 patients with immune-complexed 
HRP2, 15/18 patients (83%) were RDT-positive. For the 
group of patients with free HRP2 and no immune com-
plexes, 3/7 (43%) were RDT-positive. Several of the 
false-negative results from both groups can be attrib-
uted to low (< 1 pM in DBS extract) free HRP2 levels. 
Importantly, the false-negative RDT rate for patients 
with immune-complexed HRP2 was not higher than 
that for patients with no HRP2 immune complexes.
Discussion
Because HRP2 is so frequently used as a biomarker for 
P. falciparum malaria, it is imperative to thoroughly 
investigate potential matrix interferants that could 
result in false-positive or false-negative results in a 
diagnostic format. Recent conflicting reports call into 
question whether α-HRP2 antibodies are present in 
human host circulation and if they could interfere with 
HRP2 detection on malaria RDTs. Biswas et al. and Ho 
et  al. found circulating α-HRP2 antibodies in patient 
samples from a variety of endemic areas [25, 27]. In 
contrast, Taylor et  al. found no circulating α-HRP2 
in patients from a high-transmission region in Cam-
eroon, and Das et  al. found that HRP2 did not stimu-
late production of α-HRP2 in PBMCs isolated from 
P. falciparum-positive patients from India [26, 28]. 
Shared among all of these reports is that the presence 
or absence of freely circulating α-HRP2 was measured 
in a direct immunoassay format, in which recombinant 
HRP2 was employed as a capture reagent, and enzyme-
conjugated α-human detection antibodies were used 
to generate signal. There are a couple disadvantages to 
this approach. First, while the presence of circulating 
α-HRP2 antibodies suggests the antigen may be present 
in immune-complexed form, it does not guarantee that 
this is the case. Immune-complexed antigens could be 
only transiently present and rapidly cleared by phago-
cytes. Second, the absence of detectable, freely cir-
culating α-HRP2 does not exclude the possibility that 
immune-complexed antigen may be present, especially 
in the case when the antigen concentration is very high. 
Indeed, Ho et  al. found that samples with high HRP2 
concentrations generally had lower free circulating 
α-HRP2 than those with low levels of HRP2 [27].
For these reasons, this work approached the ques-
tion of endogenous α-HRP2 interference from a new 
angle and sought to directly interrogate the presence or 
absence of HRP2-containing immune complexes, rather 
than freely circulating α-HRP2 antibodies, in patient 







































































































Fig. 6 Concentrations of immune-complexed and total HRP2 in all HRP2-positive samples evaluated using the immune-complex pull-down assay. 
Note that the y-axis is on a logarithmic scale. Sample IDs preceded by asterisks represent patients infected with P. falciparum parasites detected by 
PCR
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optimized in this work. First, an immune complex disso-
ciation strategy was developed based on the observation 
that rapidly heating DBS extracts to 80  °C permanently 
dissociated HRP2 immune complexes. In this assay, the 
concentration of free HRP2 in DBS extracts was meas-
ured before and after heating. For mock samples consist-
ing of DBS spotted with parasitized whole blood, HRP2 
ELISA signal was completely diminished when α-HRP2 
antibodies were present in excess greater than tenfold; 
however, heat-based dissociation fully recovered HRP2 
ELISA signal. Additionally, heating did not diminish 
HRP2 signal in the absence of α-HRP2. When this proto-
col was applied to patient DBS and paired samples were 
evaluated individually, HRP2 ELISA signal was found to 
be enhanced after heating for 6 patients, with an aver-
age enhancement factor of 1.3 ± 0.2. However, no overall 
significant difference was found between untreated and 
heated samples, even for the subset of samples in which 
immune-complexed HRP2 was found. This could be due 
to the fact that, in many samples containing complexes, 
only a small percentage of the total HRP2 was in com-
plexed form, a difference that may not be discernable by 
duplicate ELISA measurements. Additionally, it is pos-
sible that other known interferants, such as rheumatoid 
factor (RF) and human α-mouse antibodies (HAMA), 
which can falsely elevate ELISA signal, were denatured 
as a result of heating, resulting in no net enhancement. 
Thus, heating samples did not prove to be effective for 
enhancing overall HRP2 detectability for all samples con-
taining immune-complexed biomarker.
The second developed assay employed protein A, pro-
tein G, and protein L-functionalized magnetic particles 
to isolate IgG and IgM from patient DBS sample extracts. 
After washing the particles to remove non-specifically 
bound material, a denaturing immunoprecipitation pro-
tocol was applied to release any HRP2 from immune 
complexes that bound to the particles. The resulting 
HRP2 signal was measured by ELISA. In mock patient 
samples, this protocol recovered 60% of immune-com-
plexed HRP2. Importantly, in parasitized whole blood 
DBS samples, HRP2 was detectable by this method 
if and only if α-HRP2 antibodies were present. These 
results indicate that there are no nonspecific interactions 
between HRP2 and the protein A, G, and L beads in the 
pull-down assay. It is important to note that, although 
parasitized whole blood samples spiked with a high affin-
ity α-HRP2 mAb is the closest possible approximation to 
patient samples, these mock samples are inherently dif-
ferent from patient samples, which may contain antibod-
ies against a multitude of malaria and other antigens.
When the pull-down assay was applied to patient DBS, 
18 samples were found to have detectable immune-com-
plexed HRP2, representing 17% of all samples and 70% of 
samples containing free HRP2. Seven samples containing 
free HRP2 did not have detectable complexed HRP2. A 
majority of samples with immune-complexed HRP2 had 
parasitaemias detectable by PCR (11/18), and nearly all of 
them (16/18) also contained free HRP2. In the context of 
previous literature, these results are significant; Ho et al. 
found that 25% of symptomatic malaria patients had cir-
culating antibodies specific for HRP2 [27]. Although the 
sample sizes in this study are small, a much larger pro-
portion of symptomatic malaria patients (11/13; 85%) 
had HRP2 present in immune-complexed form. Addi-
tionally, previous studies have suggested that endoge-
nous α-HRP2 antibodies may interfere with HRP2-based 
malaria diagnosis [25, 27, 40]. However, for nearly three 
quarters (13/18) of patients with immune-complexed 
HRP2, less than 10% of the total HRP2 present was in 
complexed form (Fig. 6). There are three potential expla-
nations for this. First is the possibility that HRP2 con-
centrations in these samples were vastly greater than the 
concentration of α-HRP2. Second, HRP2 tagged with 
endogenous α-HRP2 may be rapidly cleared by phago-
cytes, thus reducing the relative amount of complexed 
HRP2 in a sample. The high number of repeated epitopes 
on HRP2 suggests that this antigen could result in large 
immune complexes, which rapidly trigger phagocytic 
clearance [41]. Third, freely circulating α-HRP2 antibod-
ies can only access and bind soluble HRP2, which has 
been found to represent just a portion of total HRP2 in in 
vitro studies [3].
Some samples (5) had a large proportion (≥ 20%) 
of total HRP2 present in immune complexes (Fig.  6). 
Two samples (VZH130 and VZH133) with detectable 
immune-complexed HRP2 had no detectable free HRP2, 
which suggests all HRP2 present in these samples was 
complexed by α-HRP2. Both of these patients were nega-
tive by RDT. In the context of HRP2-based detection by 
RDT, a high proportion of complexed HRP2 could be 
worrisome. For example, Scherr et al. found that the vis-
ual limit of detection for one brand of malaria RDT was 
12.5–100 parasites/µl of in vitro parasite culture, depend-
ing on the experience of the reader [42]. This corre-
sponds to 6–50 pM of rcHRP2 used in this study. In this 
regime, a decrease in detectable HRP2 of 20% or more 
could be the difference between a reader categorizing a 
test as positive or negative. However, it is important to 
note that patients with a high proportion of total HRP2 
in complexed form were the exception in this study; most 
patients had relatively low amounts of complexed HRP2 
compared to free HRP2 (median 2.7%), and thus detec-
tion by RDT was not affected.
One limitation of this study is that the recovery of the 
immune complex pull-down assay was found to be 60% 
in mock patient samples. Thus, the complexed [HRP2] 
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reported herein could underestimate the true com-
plexed HPR2 concentrations. Additionally, most malaria-
infected individuals in this study were symptomatic and 
had enough free HRP2 that detection was not affected by 
immune complexes. Thus, this study effectively excludes 
the asymptomatic malaria-infected population, which 
may have lower free HRP2 levels and is thought to con-
tribute significantly to transmission in some settings [43].
Conclusions
Overall, this work describes unique methodology for 
detection of immune-complexed HRP2 and demon-
strates its utility in patient DBS samples. The data pre-
sented here provide evidence that endogenous α-HRP2 
antibodies form immune complexes with HRP2 in the 
symptomatic patient population of a low-transmission 
area in rural Southern Zambia. In most patients with 
immune-complexed HRP2, the proportion of complexed 
HRP2 was low (< 10%) compared to the total HRP2 pre-
sent, and HRP2 detection by RDT was not affected. 
Future studies investigating the prevalence and propor-
tion of immune-complexed HRP2 in asymptomatic indi-
viduals will be required to assess whether α-HRP2 affects 
RDT performance for this portion of the transmission 
reservoir.
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